Edition:
United States

Interleukin Genetics Inc (ILIU.PK)

ILIU.PK on OTC Markets Group

0.10USD
25 Jul 2016
Change (% chg)

$0.00 (+5.00%)
Prev Close
$0.10
Open
$0.10
Day's High
$0.10
Day's Low
$0.10
Volume
1,000
Avg. Vol
--
52-wk High
--
52-wk Low
--

Latest Key Developments (Source: Significant Developments)

Interleukin Q1 loss per share $0.01
Monday, 16 May 2016 08:00am EDT 

Interleukin Genetics Inc : Interleukin genetics reports first quarter 2016 financial results . Q1 loss per share $0.01 .Q1 revenue $961,000 versus $403,000.  Full Article

Interleukin Genetics appoints Mark B. Carbeau as CEO
Tuesday, 7 Apr 2015 08:00am EDT 

Interleukin Genetics Inc:Appoints Mark B. Carbeau as Chief Executive Officer and Director.Says Dr. Kenneth S. Kornman, DDS, PhD, who served as the President and CEO since August 2012, will continue to serve as President, Chief Scientific Officer and a Director.  Full Article

Interleukin Genetics expands its collaboration with Isis Pharmaceuticals for Genetic Testing Services
Monday, 9 Mar 2015 08:00am EDT 

Interleukin Genetics Inc:Announced that under the terms of its collaboration agreement with Isis Pharmaceuticals.Says the Company will provide Isis with testing kits and will prepare DNA, run genotypes and provide data for SNP genotypes for the IL-1 and LP(a) SNPs for Isis' Phase 1 clinical study evaluating its novel therapeutic, ISIS-APO(a)-LRxin healthy volunteers with elevated lipoprotein.Lp is an independent risk factor for cardiovascular disease.Says this Phase I study is the second Isis clinical study to incorporate Interleukin's genetic test into the trial design to add genetic information at the earliest phases of testing of their new product lines.  Full Article

Interleukin Genetics announces collaboration with Isis Pharmaceuticals for genetic testing services
Wednesday, 7 Jan 2015 08:00am EST 

Interleukin Genetics Inc:Says an agreement with Isis Pharmaceuticals Inc. to provide genetic testing services for Isis' Phase 2 clinical study evaluating its novel therapeutic, ISIS-APO(a)Rx, in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.  Full Article

Interleukin Genetics Inc announces appointment of interim chief financial officer - Form 8-K
Wednesday, 10 Sep 2014 04:07pm EDT 

Interleukin Genetics Inc:Appoints Stephen DiPalma, managing director of Danforth, as interim chief financial officer.Says DiPalma replaces Eliot Lurier, who resigned as chief financial officer of the company effective as of the close of business on Sept. 5, 2014.  Full Article

Interleukin Genetics Inc announces resignation of CFO -Form 8-K
Monday, 25 Aug 2014 04:08pm EDT 

Interleukin Genetics Inc:Says on Aug. 21, 2014, Eliot M. Lurier, the chief financial officer, informed the company that he was resigning in order to pursue another professional opportunity at a Boston-based academic institution with which he has had a long standing personal relationship.Says Lurier’s resignation will be effective as of the close of business on Sept. 5.  Full Article

BRIEF-T&C Medical Science to buy 20 pct stake in bento company

* Says it will by 20 percent stake in a Tokyo-based bento company on July 1